Trial Therapy’s Potential to Prevent Ovarian Cancer Relapses Supported by Mouse Study

Trial Therapy’s Potential to Prevent Ovarian Cancer Relapses Supported by Mouse Study
An investigational drug that boosts the response of natural killer (NK) cells — key players of first-line immune defenses — was recently shown to effectively decrease ovarian tumors in a mouse model of the cancer. The drug, called ALT-803, could also re-activate inactive NK cells isolated from ovarian cancer patients. Researchers now plan to study the drug candidate in a clinical trial (NCT03054909) to see if ALT-803 can prevent women with ovarian cancer, who have undergone successful chemotherapy, from relapsing. The drug is a particularly attractive treatment option since it can be administered on an outpatient basis. The study, "IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer," was published in the journal Gynecologic Oncology. NK cells are being explored as a new tool for cancer immunotherapy. Earlier studies have shown that cells isolated from healthy donors attack ovarian tumors, both in lab dishes and in patients. Studies also confirm that NK cells, isolated from the fluid in the abdomen of ovarian cancer patients, react poorly to the presence of tumors. Aiming to find a way to re-activate these cancer-fighting cells, researchers from the University of Minnesota tested ALT-803 — developed by Altor BioScience — that has been developed to stimulate signaling by the immune cytokine interleukin 15 (IL-15). This immune mediator is known to trig
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *